Increases amount of cigarette and other tobacco product tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.
Impact
The bill prioritizes cancer research funding on par with state funding dedicated to similar causes like spinal cord and brain injury research. By increasing the funding to $4 million, it is anticipated that the NJCCR will be better positioned to support original research projects and resources that benefit both healthcare providers and cancer patients in New Jersey. This change is crucial given the historical fluctuations in funding levels, where appropriations have not always met statutory requirements, impacting the commission's ability to operate effectively.
Summary
Senate Bill S1742, introduced in February 2022, proposes a significant increase in funding for cancer research in New Jersey by raising the allocation of cigarette and other tobacco products tax revenues to the New Jersey Commission on Cancer Research (NJCCR) from $1 million to $4 million. This amendment aims to establish a dedicated, non-lapsing Cancer Research Fund, which will replace the existing lapsing fund, thus ensuring more stable funding for vital research into cancer treatments and prevention. The NJCCR plays a critical role in promoting research that addresses the causes, prevention, treatment, and palliation of cancer within the state.
Contention
Though the bill has clear benefits in terms of enhanced funding for cancer research, there could be debates surrounding the implications of increasing dependence on tobacco tax revenues for funding health initiatives. Critics might argue about the ethics of using revenue from harmful products to support positive health outcomes. Additionally, ensuring that the research funded aligns with community health needs and equitable access to care may lead to discussions among legislators and stakeholders about how the funds are utilized and the accountability of the NJCCR in managing these funds.
Same As
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco product tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.